



**Department of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting
Draft Minutes**

October 22, 2024: 5:00 – 8:00 p.m.

Board Members Present:

Andy Miller, RPH	Anne Daly, PharmD	Douglas Franzoni, PharmD
Katharina Cahill, PharmD	Bram Starr, MD	Louise Rosales, APRN
Rima Carlson, MD	Julie MacDougall, PharmD	

Board Members Absent: None

DVHA Staff Present:

Carrie Germaine	Lisa Hurteau, PharmD	Ashley MacWalters
Taylor Robichaud, PharmD	Michael Rapaport, MD	

Change Healthcare Staff Present:

Upasana Bhatnagar, MD	Mike Ouellette, RPh	Molly Trayah, PharmD
------------------------------	----------------------------	-----------------------------

Guests/Members of the Public: Angela Hathaway, Adam Ferguson, Jigna Bhalla, Chad Bohigian, Cole Wyrrough, Corey O'Brien, Dennis Sholler, Kristin DiDesidero, Bryan Dillon, Susan Donnelly, Scott Ebersol, Elena Fernandez, Jai Persico, Jalal Nait Hammoud, James Sharp, Jennifer Golwyn, Richard Junk, Kevin Gaffney, Kim Ahearn, Kristen Chopas, Vincent Lawler, Mark Golick, Timothy McSherry, Nick Boyer, Nicole Pinkerton, Nikhil Kacker, Amy Cunningham, Omer Oziz, Paul Isikwe, Ryan Miller, Matt Sankey, Daniel Shan, Sharmi Patel, Timothy Birner, Tina Hartmann, Nicole Trask, Annie Vong, Megan Walsh, Lindsey Walter, Joseph Ward

- **Executive Session**
- **Introductions**
- **Approval of DUR Board Minutes**
- **DVHA Pharmacy Administration Updates**
- **DVHA Chief Medical Officer Update**
- **Follow-up Items from Previous Meetings**
 - None at this time.
- **RetroDUR/Pro DUR**
 - None at this time
- **Consent Agenda Items**
 - None at this time

- **Clinical Update: Drug Reviews**
 - None at this time
- **Therapeutic Drug Classes – Periodic Review**
 - None at this time

- **Review of Newly Developed/Revised Criteria**

- ADHD Medications

Recommendation:

- Move Methylin to non-preferred
- Move Adderall XR to non-preferred
- Move Qelbree to preferred after clinical criteria met

Board Decision: Approved

- Anticonvulsants

Recommendation:

- Remove Diastat from PDL

Board Decision: Approved

- Pulmonary Agents

Recommendation:

- Add tiotropium bromide to non-preferred
- Add Sandoz labeler to preferred albuterol HFA inhalers
- Remove ProAir Digihaler from PDL
- Remove age criteria from Asmanex HFA

Board Decision: Approved

- Anti-diabetics

Recommendation:

- Move Fiasp (insulin aspart) to preferred
- Move Humalog (insulin lispro) Kwikpen U-200 and Novolog (insulin aspart) to non-preferred
- Update non-preferred rapid acting insulin criteria
- Update intermediate-acting insulin criteria
- Move Tresiba (insulin degludec) to non-preferred and update criteria
- Update non-preferred long-acting insulin criteria
- Move Humulin 70/30 (NPH/Regular) insulin to preferred
- Move Rybelsus to preferred, after clinical criteria met
- Move Ozempic to non-preferred

- Update criteria for Adlyxin, Byetta, Bydureon, BCise, Mounjaro
- Move dapagliflozin and Invokana (canagliflozin) to non-preferred
- Move Synjardy XR to preferred
- Move Invokamet to non-preferred

Board Decision: Approved

- Antipsychotics – Children < 18 years old
Recommendation:
 - Move olanzapine orally disintegrating tablets to preferred

Board Decision: Approved

- Antipsychotics - Adults
Recommendation:
 - Update Rexulti criteria
 - Move Rykindo to preferred
 - Add Risperidone ER suspension and move Zyprexa Relprevv to non-preferred with criteria
 - Move olanzapine orally disintegrating tablets to preferred

Board Decision: Approved

- Anti-Hypertensives
Recommendation:
 - Move Hemangeol to non-preferred
 - Add Wegovy for MACE reduction to non-preferred

Board Decision: Approved

- Cytokines
Recommendation:
 - Move adalimumab-adbm to preferred for all categories
 - Ankylosing Spondylitis:
 - Add Simponi Aria vial to non-preferred
 - Gastrointestinal agents (IBD/Crohns)
 - Move Skyrizi to preferred
 - Add Entyvio subcutaneous to non-preferred
 - Add Tremfya to non-preferred
 - Hidradenitis Suppurativa
 - No additional changes
 - Psoriasis
 - Move Skyrizi to preferred

- Move tazarotene cream, gel and Vtama cream to preferred
- Rheumatoid, Juvenile, and Psoriatic Arthritis
 - Move Skyrizi to preferred
 - Move Tyenne to preferred

Board Decision: Approved

- Endometriosis/Uterine Fibroids Agents
Recommendation:

- Move Orilissa to preferred after clinical criteria are met

Board Decision: Approved

- Gastrointestinal Agents
Recommendation:

- Move Docusate enema and Enemeez enema to non-preferred
- Move Gavilyte-C and Golytely to preferred

Board Decision: Approved

- Hemophilia Treatments
Recommendation:

- Move Altuviiiio to preferred
- Move Advate, Afstyla, Kogenate, and Recombinate to non-preferred

Board Decision: Approved

- Hyperammonia Treatments
Recommendation:

- Move Carbaglu to preferred
- Move Carglumic Acid to non-preferred

Board Decision: Approved

- Immunologic Therapies for Asthma
Recommendation:

- Add criteria for diagnosis of IgE mediated food allergy to Xolair
- Add criteria for diagnosis of COPD to Dupixent

Board Decision: Approved

- Dermatological Agents
Recommendation:

- Move Opzelura to preferred after clinical criteria are met

Board Decision: Approved

- Movement Disorders
Recommendation:

- Move tetrabenazine to preferred

Board Decision: Approved

- Multiple Sclerosis Medications
Recommendation:

- Update Glatiramer, Glatopa criteria

Board Decision: Approved

- Botulinum Toxins
Recommendation:

- Move Botox and Dysport to preferred after clinical criteria are met

Board Decision: Approved

- Ophthalmics
Recommendation:

- Move Flarex to non-preferred
- Move Eysuvis to preferred
- Move Acular LS, Flubiprofen, Nevanac to preferred

Board Decision: Approved

- Pulmonary Arterial Hypertension Medications
Recommendation:

- Move Sildenafil suspension to preferred

Board Decision: Approved

- Sickle Cell Disease Therapies
Recommendation:

- Remove Oxbryta from PDL

Board Decision: Approved

- Hypothyroid Agents
Recommendation:

- Move Ermeza to preferred after clinical criteria are met

Board Decision: Approved

- Urinary Antispasmodics
Recommendation:

- Move Toviaz to non-preferred

Board Decision: Approved

- Vaginal Anti-infectives
Recommendation:

- Move Cleocin vaginal cream 2% to preferred
 - Move Xaciato to preferred
 - Move clindamycin vaginal cream 2% to non-preferred

Board Decision: Approved

- **General Announcements**
 - None at this time.
- **Adjourn**

8:02 pm